person · Reporting owner
Charlton Ralph William III
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | CHIEF MEDICAL OFFICER | December 10, 2024 | December 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SPRUCE BIOSCIENCES, INC.
Report date December 10, 2024 · Filed December 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 161,339 |
Ending reported balance
After 2024-12-16 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-12-10 · Exercise / conversion · Acquired 106,400 · Balance 161,773 F1: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F2: Each RSU represents a contingent right to receive one share of SPRB common stock. Row 2 · 2024-12-10 · Tax withholding · Disposed 37,964 · Balance 123,809 F1: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. Row 3 · 2024-12-16 · Exercise / conversion · Acquired 26,600 · Balance 150,409 F1: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F2: Each RSU represents a contingent right to receive one share of SPRB common stock. Row 4 · 2024-12-16 · Tax withholding · Disposed 9,491 · Balance 140,918 F1: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. Row 5 · 2024-12-16 · Exercise / conversion · Acquired 31,750 · Balance 172,668 F3: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares. F2: Each RSU represents a contingent right to receive one share of SPRB common stock. Row 6 · 2024-12-16 · Tax withholding · Disposed 11,329 · Balance 161,339 F3: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 106,400 |
Reported balance
After 2024-12-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-12-10 · Exercise / conversion · Disposed 106,400 · Balance 106,400 F2: Each RSU represents a contingent right to receive one share of SPRB common stock. F1: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 79,800 |
Reported balance
After 2024-12-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-12-16 · Exercise / conversion · Disposed 26,600 · Balance 79,800 F2: Each RSU represents a contingent right to receive one share of SPRB common stock. F1: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F4: Represents the aggregate balance of time-based RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 63,500 |
Reported balance
After 2024-12-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-12-16 · Exercise / conversion · Disposed 31,750 · Balance 63,500 F2: Each RSU represents a contingent right to receive one share of SPRB common stock. F3: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.
F2: Each RSU represents a contingent right to receive one share of SPRB common stock.
F3: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares.
F4: Represents the aggregate balance of time-based RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 31,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · derivative · entry 9 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,500 Underlying: Common Stock · 31,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares. F3 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 26,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · derivative · entry 8 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,800 Underlying: Common Stock · 26,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F4 · balance_after: Represents the aggregate balance of time-based RSUs. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 11,329 | $0.39 | $4,403.58 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 6 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,339 F3 · shares: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 31,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 5 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 9,491 | $0.39 | $3,689.15 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 4 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,918 F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 26,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 3 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 106,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · derivative · entry 7 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,400 Underlying: Common Stock · 106,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 37,964 | $0.54 | $20,386.67 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 2 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,809 F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 106,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 1 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:31 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 106,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008279 · form4-03182024_080353.xml · derivative · entry 1 Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,400 Underlying: Common Stock · 106,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F2 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective. F2 · derivative.expiration_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:10 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 9,361 | $0.98 | $9,150.38 |
DisclosureSEC source: 0001209191-24-000339 · doc4.xml · nonDerivative · entry 1 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,373 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:17 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 31,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059055 · doc4.xml · derivative · entry 4 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,250 Underlying: Common Stock · 31,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 31,750 RSUs vested, with 10,980 shares being withheld for taxes, resulting in a net issuance of 20,770 shares. F1 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 31,750 RSUs vested, with 10,980 shares being withheld for taxes, resulting in a net issuance of 20,770 shares. F5 · balance_after: Represents the aggregate balance of 95,250 time-based RSUs. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:17 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 10,980 | $1.66 | $18,226.80 |
DisclosureSEC source: 0001209191-23-059055 · doc4.xml · nonDerivative · entry 2 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,012 F1 · shares: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 31,750 RSUs vested, with 10,980 shares being withheld for taxes, resulting in a net issuance of 20,770 shares. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:17 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 31,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059055 · doc4.xml · nonDerivative · entry 1 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 31,750 RSUs vested, with 10,980 shares being withheld for taxes, resulting in a net issuance of 20,770 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 01:17 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 212,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059055 · doc4.xml · derivative · entry 3 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,800 Underlying: Common Stock · 212,800 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 106,400 of the RSUs shall vest as to 25% on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.exercise_date: 106,400 of the RSUs shall vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F3 · derivative.expiration_date: 106,400 of the RSUs shall vest as to 25% on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.expiration_date: 106,400 of the RSUs shall vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 12,378 | $0.98 | $12,099.50 |
DisclosureSEC source: 0001209191-23-041267 · doc4.xml · nonDerivative · entry 1 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,242 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 30, 2022 Filed Jan 6, 2023 01:13 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 12,864 | $0.93 | $11,999.54 |
DisclosureSEC source: 0001209191-23-002153 · doc4.xml · nonDerivative · entry 1 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,864 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 01:06 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 127,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060278 · doc4.xml · derivative · entry 1 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,000 Underlying: Common Stock · 127,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The RSUs vest over four years. 25% of the RSUs will vest on December 15, 2023 (the "Annual Vesting Date"), and 25% of the total number of RSUs will vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F2 · derivative.expiration_date: The RSUs vest over four years. 25% of the RSUs will vest on December 15, 2023 (the "Annual Vesting Date"), and 25% of the total number of RSUs will vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| April 01, 2022 Filed Apr 2, 2022 00:04 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001209191-22-022108 · doc4.xml · derivative · entry 1 Charlton Ralph William III · CIK 0001919397 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-03-31 F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing on the vesting commencement date of March 28, 2022 ("Vesting Commencement Date"). 1/4th of the total number of shares will vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/36th of the remaining shares will vest and become exercisable on a monthly basis thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.